Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FMEC7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,403
Award facts
- Contract value 100% obligated
- $24,403.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $24,403.40 to DMS Pharmaceutical Group Inc. for the supply of ENTYVIO 300 mg vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform the work at its facility in Park Ridge, IL 60068. This delivery order was issued without a set-aside designation, reflecting the company's competitive capability in unrestricted federal procurement. The award was made on December 29, 2025, with an ultimate completion date of December 30, 2025.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. That master contract, valued at $499.9 billion with completion through December 31, 2036, positions the company as a critical regional pharmaceutical supplier supporting Department of Defense healthcare operations worldwide. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to military healthcare facilities globally. DMS Pharmaceutical Group has demonstrated substantial federal contracting activity through numerous delivery orders issued by the DLA Medical Supply Chain division, establishing its capability to fulfill the specialized pharmaceutical requirements of the military medical system.
Quick answers
Who was awarded contract SPE2DR26FMEC7?
SPE2DR26FMEC7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FMEC7 worth?
The government has obligated $24,403 on SPE2DR26FMEC7.
Is contract SPE2DR26FMEC7 an order under another contract?
Yes. SPE2DR26FMEC7 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEC7 competed?
The extent of competition for SPE2DR26FMEC7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award